Compare Moderna, Inc. (MRNA) vs Nasdaq Inc (NDAQ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Moderna, Inc. vs Nasdaq Inc — how do they compare? Moderna, Inc. trades at $59.66 (market cap $23.60B), while Nasdaq Inc trades at $90.25 (market cap $51.96B). The key difference: Nasdaq Inc is far larger — about 2.2× Moderna, Inc.'s market cap, and Nasdaq Inc pays a 1.22% dividend while Moderna, Inc. pays none. Which is the better fit depends on your goals.
| MRNA | NDAQ | |
|---|---|---|
Market Cap | $23.60B | $51.96B |
Sector | Health | Financials |
52-Week High | $81.80 | $100.98 |
52-Week Low | $22.36 | $76.85 |
Enterprise Value | $19.70B | $59.02B |
Dividend Yield | — | 1.22% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Moderna (MRNA) trades at $59.66, down 3.49% in the last session amid broader biotech volatility. The stock shows a mixed technical picture with bullish overall signals but bearish moving averages. Fundamentally, revenue has declined from pandemic peaks to $1.92B in 2025, with net losses widening to -$2.82B. Recent positive developments include an EU RSV vaccine contract and progress in cancer immunotherapy trials, with Q2 2026 earnings due July 31.
Outlook remains speculative as Moderna transitions beyond COVID-19 vaccines. Opportunities lie in its expanding pipeline in oncology and flu vaccines, but risks include sustained losses, competitive pressure, and execution hurdles. Analyst consensus is cautious with a $49 price target below current levels, reflecting uncertainty over profitability timeline.
Nasdaq (NDAQ) trades at $90.24, down 1.53% today, with a bullish technical signal from moving averages and a consensus analyst price target of $107.00. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $0.96 exceeding expectations, and maintains robust profitability with a net income margin of 23.03%. Recent news highlights strategic growth, including the acquisition of Nasdaq Fund Secondaries by NPM, expanding its platform beyond direct company shares.
The outlook for NDAQ is positive, supported by organic revenue growth and strategic acquisitions, though risks include market volatility and execution challenges. With 61.11% of analysts rating it a buy and a price target implying ~19% upside, the stock presents a growth opportunity for investors focused on financial infrastructure expansion, balanced by monitoring debt levels and competitive pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →About Nasdaq Inc
Founded in 1971, Nasdaq is primarily known for its equity exchange, but in addition to its market-services business (about 35% of sales), the company sells and distributes market data as well as offers Nasdaq-branded indexes to asset managers and investors through its information-services segment (30%). Nasdaq's corporate-services business (20%) offers listing services and related investor relations products to publicly traded companies and through the company's market technology group (15%), Nasdaq facilitates the exchange operations of other exchanges throughout the world and provides financial compliance services.
Read more on NDAQ →
